As of Apr 01
| +0.17 / +1.17%|
The 3 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 27.50, with a high estimate of 30.00 and a low estimate of 23.00. The median estimate represents a +86.82% increase from the last price of 14.72.
The current consensus among 3 polled investment analysts is to Buy stock in Redhill Biopharma Ltd. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.